Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q2 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $30 million.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.